Alumis (ALMS) Cash from Investing Activities (2023 - 2025)
Alumis (ALMS) reported Cash from Investing Activities of $95.0 million for Q4 2025, up 206.99% year-over-year from $31.0 million in Q4 2024, and up 295.29% quarter-over-quarter from $24.0 million in Q3 2025.
Alumis (ALMS) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Cash from Investing Activities data on file, last reported at $95.0 million in Q4 2025.
- Cash from Investing Activities for Q4 2025 came in at $95.0 million, up 206.99% year-over-year; the trailing twelve-month figure through Dec 2025 was $287.9 million (up 352.99% YoY), and the FY2025 annual result was $287.9 million, up 352.99% from the prior year.
- Cash from Investing Activities improved to $95.0 million in Q4 2025 per ALMS's latest filing, from $24.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $129.4 million in Q2 2025 and troughed at -$93.2 million in Q3 2024.
- A 3-year average of $17.8 million and a median of $15.8 million in 2023 frame the typical range for Cash from Investing Activities.
- On a YoY basis, Cash from Investing Activities climbed as much as 846.86% in 2024 and fell as far as 1330.06% in 2024.
- A 3-year view of Cash from Investing Activities shows it stood at -$4.1 million in 2023, then jumped by 846.86% to $31.0 million in 2024, then soared by 206.99% to $95.0 million in 2025.
- Business Quant data shows ALMS's Cash from Investing Activities at $95.0 million in Q4 2025, $24.0 million in Q3 2025, and $129.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | 95.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 95.01 Mn |
| Dec 31, 2025 | 95.01 Mn |
| Sep 30, 2025 | 24.04 Mn |
| Sep 30, 2025 | 24.04 Mn |
| Jun 30, 2025 | 129.40 Mn |
| Jun 30, 2025 | 129.40 Mn |
| Mar 31, 2025 | 39.43 Mn |
| Mar 31, 2025 | 39.43 Mn |
| Dec 31, 2024 | 30.95 Mn |
| Dec 31, 2024 | 30.95 Mn |
| Sep 30, 2024 | -93.19 Mn |
| Sep 30, 2024 | -93.19 Mn |
| Jun 30, 2024 | -32.74 Mn |
| Jun 30, 2024 | -32.74 Mn |
| Mar 31, 2024 | -18.81 Mn |
| Mar 31, 2024 | -18.81 Mn |
| Dec 31, 2023 | -4.14 Mn |
| Dec 31, 2023 | -4.14 Mn |
| Sep 30, 2023 | 7.58 Mn |
| Sep 30, 2023 | 7.58 Mn |